The Psychedelic News Feed Transistor (https://transistor.fm) https://feeds.transistor.fm/the-psychedelic-news-feed The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field. © 2026 Psychedelic Alpha 3bb209f1-d04d-5fdb-a469-b46953bd36a3 yes Josh Hardman en Mon, 21 Sep 2026 12:04:38 +0100 Mon, 21 Sep 2026 12:05:26 +0100 https://psychedelicalpha.com https://img.transistorcdn.com/7PI_uFd55BArz_piXGoXtUvxr9iODoJWYVfphaowB-4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MDc4/NWQ1YzQ4ODk0YjVm/NzE0OWNlOTkyOWI5/MTU3OC5wbmc.jpg The Psychedelic News Feed https://psychedelicalpha.com episodic Psychedelic Alpha The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field. The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. psychedelics, psychedelic news, psychedelic medicine, psychedelic industry, clinical trials, drug development, biotechnology, neuroscience, mental health, FDA, regulation, biopharma, research, healthcare, psychedelic alpha, psychiatry, interventional psychiatry, neuroplastogens Psychedelic Alpha hello@psychedelicalpha.com No No Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers 1 1 Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers full e8f468e8-da45-4a47-ba78-7b3a86fe3dc7 https://share.transistor.fm/s/e4ec3f40 In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:

  • Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
  • A commentary published by top FDA staff outlining a model for psychedelic drug development
  • New Zealand’s approval of two psychiatrists to prescribe MDMA
  • And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.

Read more:

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:

  • Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
  • A commentary published by top FDA staff outlining a model for psychedelic drug development
  • New Zealand’s approval of two psychiatrists to prescribe MDMA
  • And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.

Read more:

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> Mon, 21 Sep 2026 11:29:28 +0100 Psychedelic Alpha Psychedelic Alpha 1094 In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:

  • Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
  • A commentary published by top FDA staff outlining a model for psychedelic drug development
  • New Zealand’s approval of two psychiatrists to prescribe MDMA
  • And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.

Read more:

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> psychedelics, psychedelic news, psychedelic medicine, psychedelic industry, clinical trials, drug development, biotechnology, neuroscience, mental health, FDA, regulation, biopharma, research, healthcare, psychedelic alpha, psychiatry, interventional psychiatry, neuroplastogens No Josh Hardman